证券代码：605033 证券简称：美邦股份 公告编号：2023-056 陕西美邦药业集团股份有限公司 第二届董事会第二十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 陕西美邦药业集团股份有限公司（以下简称"公司"）第二届董事会第二十 四次会议通知于 2023 年 8 月 18 日以电话方式通知各位董事，会议于 2023 年 8 月 28 日在公司会议室以现场及通讯表决方式召开。会议应到董事 9 人，实到董 事 9 人。会议由董事长张少武先生主持，本次会议召开符合《中华人民共和国公 司法》（以下简称"《公司法》"）及其他法律法规和《公司章程》的规定，合法有 效。经董事认真审议，通过了以下决议： 二、董事会会议审议情况 （一）审议并通过《关于公司 2023 年半年度报告及摘要的议案》 同意公司 2023 年半年度报告及摘要。 赞成票：9 票；反对票：0 票；弃权票：0 票。 本议案相关内容详见上海证券交易所网站 www.sse.com.cn《陕西美邦药业集 团股份有限公司 2023 ...

根据上海证券交易所《上海证券交易所上市公司自律监管指引第1号 —— 规范运作》和《上海证券交易所上市公司自律监管指南第1号——公告格式》的 规定，将陕西美邦药业集团股份有限公司（以下简称"本公司"或"公司"）2023 年半年度募集资金存放与使用情况报告如下： 一、募集资金基本情况 经中国证券监督管理委员会证监发行字[2021]2738 号文核准，本公司于 2021 年 9 月向社会公开发行人民币普通股（A 股）3,380.00 万股，每股发行价 为 12.69 元，应募集资金总额为人民币 42,892.20 万元，根据有关规定扣除发行 费用 3,707.86 万元后，实际募集资金金额为 39,184.34 万元。该募集资金已于 2021 年 9 月到账。上述资金到账情况已经容诚会计师事务所（特殊普通合伙） 容诚验字[2021]230Z0192 号验证。公司对募集资金采取了专户存储管理。 二、募集资金管理情况 根据有关法律法规的规定，遵循规范、安全、高效、透明的原则，公司制 定了《募集资金管理办法》，对募集资金的存储、审批、使用、管理与监督做 出了明确的规定，以在制度上保证募集资金的规范使用。 2021 年 9 ...

证券代码：605033 证券简称：美邦股份 公告编号：2023-058 陕西美邦药业集团股份有限公司 关于 2023 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责 任。 根据有关法律法规的规定，遵循规范、安全、高效、透明的原则，公司制 定了《募集资金管理办法》，对募集资金的存储、审批、使用、管理与监督做 出了明确的规定，以在制度上保证募集资金的规范使用。 单位：人民币万元 2021 年 9 月，本公司与西安银行股份有限公司雁塔支行、中国光大银行股 份有限公司西安分行营业部、招商银行股份有限公司西安南大街支行、中信银 1 根据上海证券交易所《上海证券交易所上市公司自律监管指引第1号 —— 规范运作》和《上海证券交易所上市公司自律监管指南第1号——公告格式》的 规定，将陕西美邦药业集团股份有限公司（以下简称"本公司"或"公司"）2023 年半年度募集资金存放与使用情况报告如下： 行股份有限公司西安分行、中国农业银行有限公司蒲城县支行和光大证券股份 有限公司（以下简称"光大证券"） ...

独立董事关于对公司第二届董事会第二十四次会议相关事项的 独立意见 根据中国证监会《上市公司独立董事规则》等法律法规、规范性文件以及《独 立董事工作制度》的规定，我们作为陕西美邦药业集团股份有限公司（以下简称 "公司"）的独立董事，对公司第二届董事会第二十四次会议审议的相关事项进行 了认真审议并发表如下独立意见: 一、独立董事对《关于公司 2023 年半年度募集资金存放与实际使用情况专 项报告的议案》的独立意见 陕西美邦药业集团股份有限公司 公司 2023 年半年度募集资金的存放和使用符合中国证监会、上海证券交易 所关于上市公司募集资金存放和使用的相关监管要求和管理办法,不存在募集资 金存放和使用违规的情形。公司所披露的募集资金存放和使用情况信息与实际情 况一致，如实履行了信息披露义务。 我们同意《公司 2023 年半年度募集资金存放与实际使用情况专项报告》。 (以下无正文) （本页无正文，为《陕西美邦药业集团股份有限公司独立董事关于对公司第二届 董事会第二十四次会议相关事项的独立意见》签署页 ) 蒋德权 2023 年 8 月 28 日 2 : （本页无正文，为《陕西美邦药业集团股份有限公司独立董事关于对公司第 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 344,708,419.69, a decrease of 29.30% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 69,276,052.01, down 24.50% year-on-year[5]. - The basic earnings per share decreased to CNY 0.51, reflecting a decline of 24.50%[6]. - The company reported a net profit margin of 24.7% for Q1 2023, compared to 25.8% in Q1 2022[20]. - In Q1 2023, the company's net profit was CNY 69,276,052.01, a decrease of 24.6% compared to CNY 91,752,261.05 in Q1 2022[22]. - Operating profit for Q1 2023 was CNY 79,271,153.70, down from CNY 106,982,851.88 in the same period last year, reflecting a decline of 26.0%[22]. - The total profit for Q1 2023 was CNY 79,946,102.29, down from CNY 106,934,436.60 in Q1 2022, reflecting a decrease of 25.2%[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,437,247,389.95, a decrease of 7.90% from the end of the previous year[6]. - Total assets as of March 31, 2023, were RMB 1,437,247,389.95, down from RMB 1,560,494,842.26 at the end of 2022, a decrease of 7.9%[18]. - Total liabilities decreased to RMB 281,618,625.34 from RMB 474,142,129.66, a significant reduction of 40.7%[18]. - The equity attributable to shareholders increased to RMB 1,155,628,764.61 from RMB 1,086,352,712.60, an increase of 6.4%[19]. Cash Flow and Investments - Cash flow from operating activities was negative at CNY -62,936,566.19, indicating a significant cash outflow[5]. - The cash flow from operating activities in Q1 2023 was negative at CNY -62,936,566.19, an improvement from CNY -81,768,900.40 in Q1 2022[25]. - Investment activities generated a net cash outflow of CNY -2,593,704.84 in Q1 2023, compared to a net inflow of CNY 13,871,427.04 in Q1 2022[25]. - The company reported cash and cash equivalents at the end of Q1 2023 amounting to CNY 242,286,396.44, up from CNY 91,338,101.17 at the end of Q1 2022[26]. Receivables and Inventory - Accounts receivable increased by 62.84%, primarily due to the timing of customer settlements[10]. - Accounts receivable increased to RMB 302,507,518.83 from RMB 185,766,247.94, reflecting a growth of 62.9%[17]. - Inventory decreased to RMB 331,957,925.01 from RMB 457,288,782.73, a reduction of 27.4%[17]. Expenses and Cost Management - The company experienced a 54.50% reduction in selling expenses, reflecting cost-cutting measures[10]. - Total operating costs for Q1 2023 were RMB 259,802,086.69, down 28.2% from RMB 361,683,622.68 in Q1 2022[20]. - Research and development expenses in Q1 2023 were CNY 19,925,881.93, a decrease of 22.3% from CNY 25,662,200.89 in Q1 2022[22]. - The company incurred sales expenses of CNY 21,956,508.77 in Q1 2023, compared to CNY 48,255,591.69 in Q1 2022, indicating a reduction of 54.4%[22]. Future Outlook - The company plans to focus on expanding its market presence and developing new products in the upcoming quarters[20].

证券代码：605033 证券简称：美邦股份 公告编号：2023-036 陕西美邦药业集团股份有限公司 关于举办2022年度业绩说明会暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 如有董事对临时公告内容的真实性、准确性和完整性无法保证或存在异议 的，公司应当在公告中作特别提示。 重要内容提示： 一、说明会类型 陕西美邦药业集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 20 日 在上海证券交易所网站（www.sse.com.cn）披露了《陕西美邦药业集团股份有限 会议召开时间：2023 年 05 月 05 日（星期五）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会议问题征集：投资者可于 2023 年 05 月 05 日 前 访 问 网 址 https://eseb.cn/148lqN4uW7S 或使用微信扫描下方小程序码进行会前提问， 公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注 的问题进行回答。 会议 ...

Financial Performance - The company's operating revenue for 2022 was CNY 906,045,600.11, representing a year-on-year increase of 7.54% compared to CNY 842,490,330.97 in 2021[22]. - The net profit attributable to shareholders of the listed company reached CNY 145,088,329.38, an increase of 15.38% from CNY 125,742,881.24 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 131.48 million, up 18.39% from the previous year[34]. - The basic earnings per share for 2022 was CNY 1.07, down 6.14% from CNY 1.14 in 2021[24]. - The weighted average return on equity decreased to 14.13%, down 6.48 percentage points from 20.61% in the previous year[24]. - The company reported a net profit of CNY 91,752,261.05 in the first quarter of 2022, with a significant drop in the third quarter resulting in a loss of CNY 5,200,157.13[26]. - The total net assets attributable to shareholders of the listed company increased to CNY 1,086,352,712.60, a rise of 12.35% from CNY 966,952,383.22 in 2021[23]. - The company maintained a total asset value of 1.56 billion yuan and net assets attributable to shareholders of 1.09 billion yuan[58]. - The company achieved operating revenue of 906.05 million yuan, a year-on-year increase of 7.54%[58]. - Net profit attributable to shareholders was 145.09 million yuan, up 15.38% compared to the previous year[58]. - The net cash flow from operating activities increased by 216.24%, amounting to CNY 126,411,753.13, primarily due to a decrease in raw material prices and reduced procurement expenditures[24]. Dividends and Shareholder Returns - The company plans to distribute cash dividends of 2.20 CNY per 10 shares, totaling 29,744,000 CNY for the year 2022[5]. - The cash dividend ratio accounts for 20.5% of the net profit attributable to shareholders of the listed company for the fiscal year 2022[181]. - The remaining undistributed profit amounts to CNY 443,399,115.99[177]. - The cash dividend distribution plan requires approval from the shareholders' meeting before implementation[177]. - The company has established a cash dividend policy that complies with its articles of association and shareholder resolutions[178]. - The independent directors have fulfilled their responsibilities regarding the cash dividend policy[178]. - The cash dividend distribution is fully funded from the company's undistributed profits[181]. - The company has proposed a three-year dividend return plan for shareholders from 2022 to 2024[148]. Research and Development - The company invested CNY 80.04 million in R&D, a 25.45% increase year-on-year, representing 8.83% of operating revenue[37]. - The company has established partnerships with several universities for research and development, focusing on new products in the fields of fungicides and insecticides[93]. - The company has achieved significant results in reducing waste emissions and improving production capacity and quality in pesticide formulation development[90]. - The company emphasizes the importance of technology innovation and has implemented various management systems to enhance R&D capabilities[92]. - The company plans to enhance its research and development capabilities by establishing a national-level technology center and a postdoctoral research station, focusing on new products and formulations to meet diverse market demands[123]. Market Position and Strategy - The company is constructing two key projects: a 30,000-ton new green pesticide formulation and water-soluble fertilizer production line, and a 20,000-ton pesticide raw material and intermediate production base[36]. - The company is focusing on the development of high-efficiency, low-toxicity pesticide products in response to national policies promoting green agriculture[79]. - The company has established itself as a leading enterprise in the pesticide formulation industry, recognized as a key agricultural industrialization leading enterprise in Shaanxi Province[86]. - The company has been ranked among the top 20 in China's pesticide industry formulation sales for four consecutive years, placing 15th in 2022[86]. - The company aims to enhance its competitiveness and profitability through continuous innovation and product updates[49]. - The company plans to deepen its presence in the pesticide market, leveraging successful marketing experiences and expanding its marketing network to enhance brand influence and market penetration[125]. Environmental and Sustainability Initiatives - The company is responding to national low-carbon policies and focusing on sustainable development through energy-saving and emission-reduction initiatives[39]. - The company is committed to environmental sustainability by developing efficient, low-toxicity pesticide formulations that align with market trends[130]. - The company achieved compliance with emission standards for both waste gas and wastewater during the reporting period, with average waste gas pollutant concentrations of VOC at 6.85 mg/m³ and COD in wastewater at 149.3 mg/L[194]. - The company has a valid pollution discharge permit until December 27, 2025, issued by the Weinan Ecological Environment Bureau, with major pollutants including waste gas and wastewater[193]. - The company conducted an emergency drill for environmental incidents during the reporting period, with the plan reviewed and filed with the local environmental bureau[197]. Corporate Governance and Management - The company held two shareholder meetings during the reporting period, ensuring compliance with legal and regulatory requirements[138]. - The board of directors convened 11 meetings, with independent directors providing independent opinions on major decisions[140]. - The company has established an investor relations management system to ensure timely and accurate communication with investors[144]. - The company has implemented a restricted stock incentive plan to align the interests of management with shareholders[150]. - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.74 million yuan[158]. - Zhang Shaowu resigned as General Manager due to work adjustments, and Zhang Tong was appointed as the new General Manager effective July 18, 2022[159]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[8]. - The company aims to establish a robust risk management framework to ensure compliance and operational efficiency while enhancing overall safety and quality standards[128]. - The company has implemented measures to mitigate raw material price risks, including centralized purchasing during price increases and enhancing supplier relationships[131]. - The company has not experienced any major safety or environmental incidents but acknowledges potential risks from equipment failures or operational issues[135].

证券代码：605033 证券简称：美邦股份 编号：2022 -05-10 陕西美邦药业集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-------------------------|-----------------------------|-------------------------------------------------------------------------------------------------------------| | | | | | | ☐ 特定对象调研 | ☐ 分析师会议 | | 投资者关系 | ☐ 媒体采访 | 业绩说明会 | | 活动类别 | ☐ 新闻发布会 | ☐ 路演活动 | | | ☐ 现场参观 | | | | ☐ | 其他（请文字说明其他活动内容） | | 形式 | ☐ 现场 网上 | ☐ 电话会议 | | 参与单位名称 及人员姓名 | 2021 | 年度业绩说明会暨现金分红说明会线上参加人员 | | 时间 | 2022 年 05 月 10 日 | 15:00-16:00 | | 地点 | 价值在线（ www.i ...

2022 年第三季度报告 证券代码：605033 证券简称：美邦股份 陕西美邦药业集团股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 2022 年第三季度报告 | 经营活动产生的现 | 不适用 不适用 | | | -25,016,421.51 | | 89.23% | | | --- | --- | --- | --- | --- | --- | --- | --- | | 金流量净额 | | | | | | | | | 基本每股收益（元/ | -0.04 | | 32.57% | 0.82 | | 30.98% | | | 股） | | | | | | | ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 617,645,692.70, representing a 29.71% increase compared to CNY 476,180,685.58 in the same period last year[22]. - The net profit attributable to shareholders of the listed company reached CNY 116,975,137.45, a significant increase of 68.45% from CNY 69,440,443.35 year-on-year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 106,270,404.13, up 55.47% from CNY 68,352,970.35 in the previous year[22]. - Basic earnings per share rose by 27.94% to CNY 0.87 compared to the same period last year[24]. - Net profit attributable to shareholders increased by 68.45%, driven by expanded sales and increased government subsidies[24]. - The company achieved operating revenue of 617,645,692.70 CNY, a year-on-year increase of 29.71%[52]. - Net profit attributable to shareholders reached 11,697.51 million CNY, up 68.45% compared to the same period last year[52]. - The company reported a significant increase in revenue for the first half of 2022, achieving a total of 1.2 billion RMB, representing a year-over-year growth of 15%[119]. Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -111,749,127.85, an improvement of 35.55% compared to CNY -173,380,608.93 in the same period last year[22]. - The total assets decreased by 0.81% to CNY 1,451,549,098.91 compared to the end of the previous year[23]. - The total current assets as of June 30, 2022, amounted to RMB 1,170,222,860.37, a decrease from RMB 1,192,777,686.41 at the beginning of the period[149]. - Cash and cash equivalents decreased to RMB 242,586,895.69 from RMB 254,387,561.65[149]. - Accounts receivable increased significantly to RMB 402,815,374.47 from RMB 90,143,475.22, indicating a substantial rise in credit sales[149]. - The total cash inflow from financing activities was CNY 130,701,980.00, compared to CNY 52,717,080.00 in the same period last year, indicating an increase of approximately 147.5%[166]. Research and Development - In the first half of 2022, the company's R&D expenses amounted to 37.84 million yuan, accounting for 6.13% of its operating revenue, indicating a commitment to innovation[43]. - Research and development expenses increased by 33.13% to 37,842,804.61 CNY, reflecting a commitment to innovation[53]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficacy and safety[113]. - The company emphasizes R&D investment to develop efficient, low-toxicity, and environmentally friendly pesticide formulations to achieve product differentiation[66]. Market Position and Strategy - The company is positioned among the top 20 pesticide formulation manufacturers in China, indicating strong market competitiveness[30]. - The company ranked 15th in the national pesticide industry formulation sales TOP100 in 2022, reflecting its strong market position[37]. - The company plans to continue focusing on its core business while expanding product categories and business channels to enhance competitiveness[34]. - The agricultural chemical industry is experiencing increased demand and price growth due to global food security concerns, benefiting domestic pesticide manufacturers[50]. - The company has implemented a strategy focusing on core crops and pest control solutions, leading to steady performance improvement despite external challenges[37]. Environmental Compliance - The company’s environmental management system has been certified to meet the GB/T24001-2016/ISO14001:2015 standards, ensuring compliance with environmental regulations[80]. - The company holds a valid Pollutant Discharge Permit until December 27, 2025, with major pollutants including waste gas and wastewater[81]. - The company achieved compliance with pollutant discharge standards for both waste gas and wastewater during the reporting period[82]. - The company has implemented effective pollution control measures, including UV photolysis and activated carbon adsorption for waste gas treatment[83]. - No significant violations of environmental laws or regulations occurred during the reporting period, nor were there any environmental pollution accidents[96]. Future Outlook - The company expects a revenue growth of 10% for the second half of 2022, projecting total revenue to reach approximately 3.3 billion RMB for the full year[114]. - New product launches are anticipated to contribute an additional 500 million RMB in revenue by the end of 2022[112]. - Market expansion plans include entering two new provinces, which are expected to increase market share by 5%[114]. - The company has committed to maintaining a dividend payout ratio of 30% of net profits for the fiscal year[114]. Shareholder and Governance - The company has committed to minimizing investor losses and will submit proposals for shareholder approval[122]. - The company assures that all shareholders possess the necessary legal qualifications to hold shares, with no violations of regulations regarding shareholding[123]. - The company will not distribute profits to shareholders who fail to fulfill public commitments[121]. - The company has established measures to avoid conflicts of interest among its major shareholders and actual controllers[123].